Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Gastrointestinal
Study Name
S0820: A double blind placebo controlled trial of Eflornithine and Sulindac to prevent recurrence of High Risk Adenomas and second primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III-preventing adenomas of the Colon with Eflornithineand Sulindac (PACES)
Principal Investigator
Gordon Srkalovic MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT01349881?term=S0820&rank=1
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance